Market Overview

UPDATE: JP Morgan Initiates Infinity Pharmaceuticals at Overweight on Positive Data

Related INFI
Infinity Announces Clinical And Preclincal Data For Duvelisib To Be Presented at ASH 2014 Annual Meeting
Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma

JP Morgan initiated coverage on Infinity Pharmaceuticals (NASDAQ: INFI) with an Overweight rating and a $42.00 price target.

JP Morgan commented, "We are initiating coverage of Infinity Pharmaceuticals with an Overweight rating based on the potential of IPI-145, the company's wholly owned, possibly best-in-class oral drug candidate for the treatment of hematologic (blood) cancers, which we believe is a billion-dollar-plus opportunity. In our view, 2013 is shaping up as another event-driven year for INFI. The stock has had an impressive run, we believe based on promising early data and recent market precedent (set by PCYC in particular)."

Infinity Pharmaceuticals closed at $33.37 on Wednesday.

Latest Ratings for INFI

DateFirmActionFromTo
Nov 2014NomuraMaintainsNeutral
Oct 2014Stifel NicolausInitiates Coverage onHold
Sep 2014JMP SecuritiesUpgradesMarket PerformMarket Outperform

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Initiation Analyst Ratings

 

Related Articles (INFI)

Around the Web, We're Loving...

Get Benzinga's Newsletters